Atherosclerosis development:lipoproteins and beyond by van Kuijk, Kim et al.
 
 
 
Atherosclerosis development
Citation for published version (APA):
van Kuijk, K., Baker, A. H., & Sluimer, J. C. (2017). Atherosclerosis development: lipoproteins and
beyond. Current Opinion in Lipidology, 28(6), 520-521. https://doi.org/10.1097/MOL.0000000000000462
Document status and date:
Published: 01/12/2017
DOI:
10.1097/MOL.0000000000000462
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 08 Jan. 2021
D
ow
nloaded
from
http://journals.lw
w
.com
/co-lipidology
by
BhD
M
f5ePH
Kav1zEoum
1tQ
fN
4a+kJLhEZgbsIH
o4XM
i0hC
yw
C
X1AW
nYQ
p/IlQ
rH
D
3i3D
0O
dR
yi7TvSFl4C
f3VC
1y0abggQ
ZXdtw
nfKZBYtw
s=
on
12/23/2020
Downloadedfromhttp://journals.lww.com/co-lipidologybyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws=on12/23/2020
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
 CURRENTOPINION Atherosclerosis development: lipoproteins
and beyond
Kim van Kuijka, Andrew H. Bakera,b, and Judith C. Sluimera,b
Even the most sceptical cardiovascular scientists can
now rest assured: LDL demonstrates a causal rela-
tionship to atherosclerotic cardiovascular disease
(CVD) [1
&&
]. A combined dataset of meta-analyses
of over 200 cohort-based, mendelian randomiza-
tion, and randomized trials covering 2 million sub-
jects, followed for more than 20 million person years
with more than 150 000 major adverse cardiovascu-
lar events (MACEs) showed 1) a dose-dependent
linear relationship between LDL-c levels and MACE,
and 2) if LDL plasma particles are reduced without
off-target effects, the risk of MACE is reduced. This is
timely news in light of recent clinical outcomes
concerning a new type of LDL-lowering compound,
proprotein convertase subtilisin/kexin type 9
(PCKS9) antibody inhibitors, such as evolocumab,
bococizumab, and alirocumab [2–4]. These antibod-
ies prevent degradation of the LDL receptor, lower
plasma LDL by60% on top of statin treatment, and
associated MACE by 15% (reviewed in [5]). Although
this represents one of the most effective and fastest
developments in recent years, it remains that 74
patients need to be treated with evolocumab to
prevent one major event. This leaves considerable
room for new therapeutic approaches. This could
possibly be provided by anti-inflammatory treat-
ment, such as IL1-b inhibitor canakinumab, clinical
results of which are eagerly awaited at ESC 2017
[6,7]. Nevertheless, more insight in the pathogenesis
of atherosclerosis is still warranted and a welcome
recommendation on the design, execution, and
reporting of murine atherosclerosis studies will
ensure reproducibility of animal pathogenesis stud-
ies and, hopefully, improve translation of mecha-
nisms to human disease [8,9
&&
].
Growing evidence points toward the highly
plastic nature of vascular smooth muscle cells
(SMCs) [10–12], endothelial cells [13], and macro-
phages [14] in the development of experimental
atherosclerosis. Adding to recent insights on plaque
macrophages originating, at least partly, from cho-
lesterol-loaded SMC [10–12], recent papers now
report on a reciprocal transition between adventitial
progenitors and plaque-residing SMCs [15
&
,16
&&
].
Majesky et al. show evidence to support SMCs as
the source of a subpopulation of adventitial progen-
itors [16
&&
], while previous reports support the
reverse transition [15
&
].
In addition, the contribution of proliferation
and clonal expansion of resident vessel wall cells
receives increasing attention. Chappell et al. show
conclusively that Acta2þ and MAC3þ SMC popu-
lations in lesions can arise from a subset of Myh11þ
SMCs visualized by multicolor lineage labelling in
mice [17
&&
]. However, Gomez and Owens addressed
some further clarifications that are needed in their
accompanying editorial, concerning clonal expan-
sion versus clonal selection and the mechanistic
contribution of such defined populations to SMC
function and lesion development, necessitating
further research [18
&
].
Related to clonal expansion, two studies now
show compelling evidence that an ageing-associated
mutation of TET2 in bone marrow can cause clonal
hematopoiesis and accelerate murine atherosclero-
sis [19
&
,20
&&
]. Moreover, patients with otherwise
unexplained clonal hematopoiesis have a two-fold
higher risk of coronary heart disease [20
&&
]. As this
mutation is associated with early-onset myocardial
infarction, monitoring of clonal expansion and
mutation analysis might improve current risk
prediction.
The amount of factors influencing plaque pro-
gression is still greatly underestimated and further
research into key mechanisms including cell plas-
ticity and clonal expansion is still needed. New
therapy strategies to combine with existing thera-
pies could greatly improve patient treatment.
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